Recent developments and perspectives in the investigation of probiotic effects

International Journal of Medical Microbiology

Volumn 300, Issue 1, 2010, Pages 3-10

  Wohlgemuth, Steffen ^a   Loh, Gunnar ^a   Blaut, Michael ^a  

^a GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

Author keywords

Animal models; Inflammatory bowel diseases; Probiotic mechanisms

Indexed keywords

DEFENSIN; PROBIOTIC AGENT;

CROHN DISEASE; DISEASE MODEL; GNOTOBIOTICS; HOST PATHOGEN INTERACTION; HOST RESISTANCE; HUMAN; IMMUNOMODULATION; IMMUNOPATHOGENESIS; INFLAMMATION; INTESTINE FLORA; NONHUMAN; SHORT SURVEY; ULCERATIVE COLITIS;

ANTIBIOSIS; BACTERIA; HUMANS; IMMUNOMODULATION; PROBIOTICS;

EID: 71649084960     PISSN: 14384221     EISSN: 16180607     Source Type: Journal    
DOI: 10.1016/j.ijmm.2009.08.003     Document Type: Short Survey

References (90)

1. Alakomi H.L., Skytta E., Saarela M., Mattila-Sandholm T., Latva-Kala K., and Helander I.M. Lactic acid permeabilizes gram-negative bacteria by disrupting the outer membrane. Appl. Environ. Microbiol. 66 (2000) 2001-2005
2. Altenhoefer A., Oswald S., Sonnenborn U., Enders C., Schulze J., Hacker J., and Oelschlaeger T.A. The probiotic Escherichia coli strain Nissle 1917 interferes with invasion of human intestinal epithelial cells by different enteroinvasive bacterial pathogens. FEMS Immunol. Med. Microbiol. 40 (2004) 223-229
3. Ayabe T., Satchell D.P., Wilson C.L., Parks W.C., Selsted M.E., and Ouellette A.J. Secretion of microbicidal alpha-defensins by intestinal Paneth cells in response to bacteria. Nat. Immunol. 1 (2000) 113-118
4. Backhed F., Ding H., Wang T., Hooper L.V., Koh G.Y., Nagy A., Semenkovich C.F., and Gordon J.I. The gut microbiota as an environmental factor that regulates fat storage. Proc. Natl. Acad. Sci. USA 101 (2004) 15718-15723
5. Barc M.C., Charrin-Sarnel C., Rochet V., Bourlioux F., Sandre C., Boureau H., Dore J., and Collignon A. Molecular analysis of the digestive microbiota in a gnotobiotic mouse model during antibiotic treatment: Influence of Saccharomyces boulardii. Anaerobe 14 (2008) 229-233
6. Bierbaum G., and Sahl H.G. Lantibiotics: mode of action, biosynthesis and bioengineering. Curr. Pharm. Biotechnol. 10 (2009) 2-18
7. Bleich A., Sundberg J.P., Smoczek A., von Wasielewski R., de Buhr M.F., Janus L.M., Julga G., Ukena S.N., Hedrich H.J., and Gunzer F. Sensitivity to Escherichia coli Nissle 1917 in mice is dependent on environment and genetic background. Int. J. Exp. Pathol. 89 (2008) 45-54
8. Borruel N., Carol M., Casellas F., Antolin M., de Lara F., Espin E., Naval J., Guarner F., and Malagelada J.R. Increased mucosal tumour necrosis factor alpha production in Crohn's disease can be downregulated ex vivo by probiotic bacteria. Gut 51 (2002) 659-664
9. Boudeau J., Glasser A.L., Julien S., Colombel J.F., and Darfeuille-Michaud A. Inhibitory effect of probiotic Escherichia coli strain Nissle 1917 on adhesion to and invasion of intestinal epithelial cells by adherent-invasive E. coli strains isolated from patients with Crohn's disease. Aliment. Pharmacol. Ther. 18 (2003) 45-56
10. Bousvaros A., Guandalini S., Baldassano R.N., Botelho C., Evans J., Ferry G.D., Goldin B., Hartigan L., Kugathasan S., Levy J., Murray K.F., Oliva-Hemker M., Rosh J.R., Tolia V., Zholudev A., Vanderhoof J.A., and Hibberd P.L. A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease. Inflamm. Bowel Dis. 11 (2005) 833-839
11. Bowey E., Adlercreutz H., and Rowland I. Metabolism of isoflavones and lignans by the gut microflora: a study in germ-free and human flora associated rats. Food Chem. Toxicol. 41 (2003) 631-636
12. Bry L., Falk P.G., Midtvedt T., and Gordon J.I. A model of host-microbial interactions in an open mammalian ecosystem. Science 273 (1996) 1380-1383
13. Canani R.B., Cirillo P., Terrin G., Cesarano L., Spagnuolo M.I., De Vincenzo A., Albano F., Passariello A., De Marco G., Manguso F., and Guarino A. Probiotics for treatment of acute diarrhoea in children: randomised clinical trial of five different preparations. BMJ 335 (2007) 340
14. Cario E. Bacterial interactions with cells of the intestinal mucosa: Toll-like receptors and NOD2. Gut 54 (2005) 1182-1193
15. Chung Y.W., Choi J.H., Oh T.Y., Eun C.S., and Han D.S. Lactobacillus casei prevents the development of dextran sulphate sodium-induced colitis in Toll-like receptor 4 mutant mice. Clin. Exp. Immunol. 151 (2008) 182-189
16. Collado M.C., Meriluoto J., and Salminen S. Role of commercial probiotic strains against human pathogen adhesion to intestinal mucus. Lett. Appl. Microbiol. 45 (2007) 454-460
17. De Keersmaecker S.C., Verhoeven T.L., Desair J., Marchal K., Vanderleyden J., and Nagy I. Strong antimicrobial activity of Lactobacillus rhamnosus GG against Salmonella typhimurium is due to accumulation of lactic acid. FEMS Microbiol. Lett. 259 (2006) 89-96
18. Dewhirst F.E., Chien C.C., Paster B.J., Ericson R.L., Orcutt R.P., Schauer D.B., and Fox J.G. Phylogeny of the defined murine microbiota: altered Schaedler flora. Appl. Environ. Microbiol. 65 (1999) 3287-3292
19. Dieleman L.A., Goerres M.S., Arends A., Sprengers D., Torrice C., Hoentjen F., Grenther W.B., and Sartor R.B. Lactobacillus GG prevents recurrence of colitis in HLA-B27 transgenic rats after antibiotic treatment. Gut 52 (2003) 370-376
20. Ewaschuk J.B., Diaz H., Meddings L., Diederichs B., Dmytrash A., Backer J., Looijer-van Langen M., and Madsen K.L. Secreted bioactive factors from Bifidobacterium infantis enhance epithelial cell barrier function. Am. J. Physiol. Gastrointest. Liver Physiol. 295 (2008) G1025-1034
21. Fitzpatrick L.R., Small J., Hoerr R.A., Bostwick E.F., Maines L., and Koltun W.A. In vitro and in vivo effects of the probiotic Escherichia coli strain M-17: immunomodulation and attenuation of murine colitis. Br. J. Nutr. 100 (2008) 530-541
22. Frick J.S., Schenk K., Quitadamo M., Kahl F., Koberle M., Bohn E., Aepfelbacher M., and Autenrieth I.B. Lactobacillus fermentum attenuates the proinflammatory effect of Yersinia enterocolitica on human epithelial cells. Inflamm. Bowel Dis. 13 (2007) 83-90
23. Fujita H., Eishi Y., Ishige I., Saitoh K., Takizawa T., Arima T., and Koike M. Quantitative analysis of bacterial DNA from mycobacteria spp., Bacteroides vulgatus, and Escherichia coli in tissue samples from patients with inflammatory bowel diseases. J. Gastroenterol. 37 (2002) 509-516
24. Fuller R. Probiotics in man and animals. J. Appl. Bacteriol. 66 (1989) 365-378
25. Gaudier E., Michel C., Segain J.P., Cherbut C., and Hoebler C. The VSL#3 probiotic mixture modifies microflora but does not heal chronic dextran-sodium sulfate-induced colitis or reinforce the mucus barrier in mice. J. Nutr. 135 (2005) 2753-2761
26. Grabig A., Paclik D., Guzy C., Dankof A., Baumgart D.C., Erckenbrecht J., Raupach B., Sonnenborn U., Eckert J., Schumann R.R., Wiedenmann B., Dignass A.U., and Sturm A. Escherichia coli strain Nissle 1917 ameliorates experimental colitis via Toll-like receptor 2- and Toll-like receptor 4-dependent pathways. Infect. Immun. 74 (2006) 4075-4082
27. Hart A.L., Lammers K., Brigidi P., Vitali B., Rizzello F., Gionchetti P., Campieri M., Kamm M.A., Knight S.C., and Stagg A.J. Modulation of human dendritic cell phenotype and function by probiotic bacteria. Gut 53 (2004) 1602-1609
28. Henker J., Laass M., Blokhin B.M., Bolbot Y.K., Maydannik V.G., Elze M., Wolff C., and Schulze J. The probiotic Escherichia coli strain Nissle 1917 (EcN) stops acute diarrhoea in infants and toddlers. Eur. J. Pediatr. 166 (2007) 311-318
29. Henker J., Laass M.W., Blokhin B.M., Maydannik V.G., Bolbot Y.K., Elze M., Wolff C., Schreiner A., and Schulze J. Probiotic Escherichia coli Nissle 1917 versus placebo for treating diarrhea of greater than 4 days duration in infants and toddlers. Pediatr. Infect. Dis. J. 27 (2008) 494-499
30. Henker J., Muller S., Laass M.W., Schreiner A., and Schulze J. Probiotic Escherichia coli Nissle 1917 (EcN) for successful remission maintenance of ulcerative colitis in children and adolescents: an open-label pilot study. Z. Gastroenterol. 46 (2008) 874-875
31. Hoentjen F., Welling G.W., Harmsen H.J., Zhang X., Snart J., Tannock G.W., Lien K., Churchill T.A., Lupicki M., and Dieleman L.A. Reduction of colitis by prebiotics in HLA-B27 transgenic rats is associated with microflora changes and immunomodulation. Inflamm. Bowel Dis. 11 (2005) 977-985
32. Hooper L.V., Xu J., Falk P.G., Midtvedt T., and Gordon J.I. A molecular sensor that allows a gut commensal to control its nutrient foundation in a competitive ecosystem. Proc. Natl. Acad. Sci. USA 96 (1999) 9833-9838
33. Hooper L.V., Wong M.H., Thelin A., Hansson L., Falk P.G., and Gordon J.I. Molecular analysis of commensal host-microbial relationships in the intestine. Science 291 (2001) 881-884
34. Hooper L.V., Stappenbeck T.S., Hong C.V., and Gordon J.I. Angiogenins: a new class of microbicidal proteins involved in innate immunity. Nat. Immunol. 4 (2003) 269-273
35. Hormannsperger G., Clavel T., Hoffmann M., Reiff C., Kelly D., Loh G., Blaut M., Holzlwimmer G., Laschinger M., and Haller D. Post-translational inhibition of IP-10 secretion in IEC by probiotic bacteria: impact on chronic inflammation. PLoS ONE 4 (2009) e4365
36. Ishikawa H., Akedo I., Umesaki Y., Tanaka R., Imaoka A., and Otani T. Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. J. Am. Coll. Nutr. 22 (2003) 56-63
37. Kinoshita H., Wakahara N., Watanabe M., Kawasaki T., Matsuo H., Kawai Y., Kitazawa H., Ohnuma S., Miura K., Horii A., and Saito T. Cell surface glyceraldehyde-3-phosphate dehydrogenase (GAPDH) of Lactobacillus plantarum LA 318 recognizes human A and B blood group antigens. Res. Microbiol. 159 (2008) 685-691
38. Kotlowski R., Bernstein C.N., Sepehri S., and Krause D.O. High prevalence of Escherichia coli belonging to the B2+D phylogenetic group in inflammatory bowel disease. Gut 56 (2007) 669-675
39. Kruis W., Fric P., Pokrotnieks J., Lukas M., Fixa B., Kascak M., Kamm M.A., Weismueller J., Beglinger C., Stolte M., Wolff C., and Schulze J. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 53 (2004) 1617-1623
40. Kuhbacher T., Ott S.J., Helwig U., Mimura T., Rizzello F., Kleessen B., Gionchetti P., Blaut M., Campieri M., Folsch U.R., Kamm M.A., and Schreiber S. Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis. Gut 55 (2006) 833-841
41. Lan J.G., Cruickshank S.M., Singh J.C., Farrar M., Lodge J.P., Felsburg P.J., and Carding S.R. Different cytokine response of primary colonic epithelial cells to commensal bacteria. World J. Gastroenterol. 11 (2005) 3375-3384
42. Lee H.S., Han S.Y., Bae E.A., Huh C.S., Ahn Y.T., Lee J.H., and Kim D.H. Lactic acid bacteria inhibit proinflammatory cytokine expression and bacterial glycosaminoglycan degradation activity in dextran sulfate sodium-induced colitic mice. Int. Immunopharmacol. 8 (2008) 574-580
43. Ley R.E., Turnbaugh P.J., Klein S., and Gordon J.I. Microbial ecology: human gut microbes associated with obesity. Nature 444 (2006) 1022-1023
44. Lin C.K., Tsai H.C., Lin P.P., Tsen H.Y., and Tsai C.C. Lactobacillus acidophilus LAP5 able to inhibit the Salmonella choleraesuis invasion to the human Caco-2 epithelial cell. Anaerobe 14 (2008) 251-255
45. Macfarlane G.T., Macfarlane S., and Gibson G.R. Validation of a three-stage compound continuous culture system for investigating the effect of retention time on the ecology and metabolism of bacteria in the human colon. Microb. Ecol. 35 (1998) 180-187
46. Makras L., Triantafyllou V., Fayol-Messaoudi D., Adriany T., Zoumpopoulou G., Tsakalidou E., Servin A., and De Vuyst L. Kinetic analysis of the antibacterial activity of probiotic lactobacilli towards Salmonella enterica serovar Typhimurium reveals a role for lactic acid and other inhibitory compounds. Res. Microbiol. 157 (2006) 241-247
47. Mallett A.K., Bearne C.A., Rowland I.R., Farthing M.J., Cole C.B., and Fuller R. The use of rats associated with a human faecal flora as a model for studying the effects of diet on the human gut microflora. J. Appl. Bacteriol. 63 (1987) 39-45
48. Menard O., Butel M.J., Gaboriau-Routhiau V., and Waligora-Dupriet A.J. Gnotobiotic mouse immune response induced by Bifidobacterium sp. strains isolated from infants. Appl. Environ. Microbiol. 74 (2008) 660-666
49. Miettinen M., Veckman V., Latvala S., Sareneva T., Matikainen S., and Julkunen I. Live Lactobacillus rhamnosus and Streptococcus pyogenes differentially regulate Toll-like receptor (TLR) gene expression in human primary macrophages. J. Leukoc. Biol. 84 (2008) 1092-1100
50. Minekus M., Smeets-Peeters M., Bernalier A., Marol-Bonnin S., Havenaar R., Marteau P., Alric M., Fonty G., and Huis in't Veld J.H. A computer-controlled system to simulate conditions of the large intestine with peristaltic mixing, water absorption and absorption of fermentation products. Appl. Microbiol. Biotechnol. 53 (1999) 108-114
51. Mohan R., Koebnick C., Schildt J., Mueller M., Radke M., and Blaut M. Effects of Bifidobacterium lactis supplementation on body weight, fecal pH, acetate, lactate, calprotectin and IgA in preterm infants. Pediatr. Res. 64 (2008) 418-422
52. Mukai T., Kaneko S., Matsumoto M., and Ohori H. Binding of Bifidobacterium bifidum and Lactobacillus reuteri to the carbohydrate moieties of intestinal glycolipids recognized by peanut agglutinin. Int. J. Food Microbiol. 90 (2004) 357-362
53. Nanda Kumar N.S., Balamurugan R., Jayakanthan K., Pulimood A., Pugazhendhi S., and Ramakrishna B.S. Probiotic administration alters the gut flora and attenuates colitis in mice administered dextran sodium sulfate. J. Gastroenterol. Hepatol. 23 (2008) 1834-1839
54. O'Hara A.M., O'Regan P., Fanning A., O'Mahony C., Macsharry J., Lyons A., Bienenstock J., O'Mahony L., and Shanahan F. Functional modulation of human intestinal epithelial cell responses by Bifidobacterium infantis and Lactobacillus salivarius. Immunology 118 (2006) 202-215
55. Otte J.M., and Podolsky D.K. Functional modulation of enterocytes by gram-positive and gram-negative microorganisms. Am. J. Physiol. Gastrointest. Liver Physiol. 286 (2004) G613-626
56. Parassol N., Freitas M., Thoreux K., Dalmasso G., Bourdet-Sicard R., and Rampal P. Lactobacillus casei DN-114 001 inhibits the increase in paracellular permeability of enteropathogenic Escherichia coli-infected T84 cells. Res. Microbiol. 156 (2005) 256-262
57. Rachmilewitz D., Katakura K., Karmeli F., Hayashi T., Reinus C., Rudensky B., Akira S., Takeda K., Lee J., Takabayashi K., and Raz E. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology 126 (2004) 520-528
58. Rembacken B.J., Snelling A.M., Hawkey P.M., Chalmers D.M., and Axon A.T. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 354 (1999) 635-639
59. Resta-Lenert S., and Barrett K.E. Probiotics and commensals reverse TNF-alpha- and IFN-gamma-induced dysfunction in human intestinal epithelial cells. Gastroenterology 130 (2006) 731-746
60. Saavedra J.M., Bauman N.A., Oung I., Perman J.A., and Yolken R.H. Feeding of Bifidobacterium bifidum and Streptococcus thermophilus to infants in hospital for prevention of diarrhoea and shedding of rotavirus. Lancet 344 (1994) 1046-1049
61. Sambuy Y., De Angelis I., Ranaldi G., Scarino M.L., Stammati A., and Zucco F. The Caco-2 cell line as a model of the intestinal barrier: influence of cell and culture-related factors on Caco-2 cell functional characteristics. Cell Biol. Toxicol. 21 (2005) 1-26
62. Samuel B.S., and Gordon J.I. A humanized gnotobiotic mouse model of host-archaeal-bacterial mutualism. Proc. Natl. Acad. Sci. USA 103 (2006) 10011-10016
63. Sartor R.B. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat. Clin. Pract. Gastroenterol. Hepatol. 3 (2006) 390-407
64. Sartor R.B. Microbial influences in inflammatory bowel diseases. Gastroenterology 134 (2008) 577-594
65. Schaedler R.W., Dubos R., and Costello R. The development of the bacterial flora in the gastrointestinal tract of mice. J. Exp. Med. 122 (1965) 59-66
66. Schlee M., Wehkamp J., Altenhoefer A., Oelschlaeger T.A., Stange E.F., and Fellermann K. Induction of human beta-defensin 2 by the probiotic Escherichia coli Nissle 1917 is mediated through flagellin. Infect. Immun. 75 (2007) 2399-2407
67. Schlee M., Harder J., Koten B., Stange E.F., Wehkamp J., and Fellermann K. Probiotic lactobacilli and VSL#3 induce enterocyte beta-defensin 2. Clin. Exp. Immunol. 151 (2008) 528-535
68. Schultz M., Linde H.J., Lehn N., Zimmermann K., Grossmann J., Falk W., and Scholmerich J. Immunomodulatory consequences of oral administration of Lactobacillus rhamnosus strain GG in healthy volunteers. J. Dairy Res. 70 (2003) 165-173
69. Schultz M., Timmer A., Herfarth H.H., Sartor R.B., Vanderhoof J.A., and Rath H.C. Lactobacillus GG in inducing and maintaining remission of Crohn's disease. BMC Gastroenterol. 4 (2004) 5
70. Sherman P.M., Johnson-Henry K.C., Yeung H.P., Ngo P.S., Goulet J., and Tompkins T.A. Probiotics reduce enterohemorrhagic Escherichia coli O157:H7- and enteropathogenic E. coli O127:H6-induced changes in polarized T84 epithelial cell monolayers by reducing bacterial adhesion and cytoskeletal rearrangements. Infect. Immun. 73 (2005) 5183-5188
71. Shida K., and Nanno M. Probiotics and immunology: separating the wheat from the chaff. Trends Immunol. 29 (2008) 565-573
72. Smits H.H., Engering A., van der Kleij D., de Jong E.C., Schipper K., van Capel T.M., Zaat B.A., Yazdanbakhsh M., Wierenga E.A., van Kooyk Y., and Kapsenberg M.L. Selective probiotic bacteria induce IL-10-producing regulatory T cells in vitro by modulating dendritic cell function through dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin. J. Allergy Clin. Immunol. 115 (2005) 1260-1267
73. Spanhaak S., Havenaar R., and Schaafsma G. The effect of consumption of milk fermented by Lactobacillus casei strain Shirota on the intestinal microflora and immune parameters in humans. Eur. J. Clin. Nutr. 52 (1998) 899-907
74. Sturm A., Rilling K., Baumgart D.C., Gargas K., Abou-Ghazale T., Raupach B., Eckert J., Schumann R.R., Enders C., Sonnenborn U., Wiedenmann B., and Dignass A.U. Escherichia coli Nissle 1917 distinctively modulates T-cell cycling and expansion via Toll-like receptor 2 signaling. Infect. Immun. 73 (2005) 1452-1465
75. Sun J., Le G.W., Shi Y.H., and Su G.W. Factors involved in binding of Lactobacillus plantarum Lp6 to rat small intestinal mucus. Lett. Appl. Microbiol. 44 (2007) 79-85
76. Turnbaugh P.J., Ley R.E., Hamady M., Fraser-Liggett C.M., Knight R., and Gordon J.I. The human microbiome project. Nature 449 (2007) 804-810
77. Ukena S.N., Westendorf A.M., Hansen W., Rohde M., Geffers R., Coldewey S., Suerbaum S., Buer J., and Gunzer F. The host response to the probiotic Escherichia coli strain Nissle 1917: specific up-regulation of the proinflammatory chemokine MCP-1. BMC Med. Genet. 6 (2005) 43
78. Ukena S.N., Singh A., Dringenberg U., Engelhardt R., Seidler U., Hansen W., Bleich A., Bruder D., Franzke A., Rogler G., Suerbaum S., Buer J., Gunzer F., and Westendorf A.M. Probiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity. PLoS ONE 2 (2007) e1308
79. Vanderpool C., Yan F., and Polk D.B. Mechanisms of probiotic action: implications for therapeutic applications in inflammatory bowel diseases. Inflamm. Bowel Dis. 14 (2008) 1585-1596
80. Vetrano S., Correale C., Borroni E.M., Pagano N., Savino B., Locati M., Malesci A., Repici A., and Danese S. Colifagina, a novel preparation of 8 lysed bacteria ameliorates experimental colitis. Int. J. Immunopathol. Pharmacol. 21 (2008) 401-407
81. Wagner R.D., Johnson S.J., and Kurniasih Rubin D. Probiotic bacteria are antagonistic to Salmonella enterica and Campylobacter jejuni and influence host lymphocyte responses in human microbiota-associated immunodeficient and immunocompetent mice. Mol. Nutr. Food Res. 53 (2009) 377-388
82. Wehkamp J., Harder J., Wehkamp K., Wehkamp-von Meissner B., Schlee M., Enders C., Sonnenborn U., Nuding S., Bengmark S., Fellermann K., Schroder J.M., and Stange E.F. NF-kappaB- and AP-1-mediated induction of human beta defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917: a novel effect of a probiotic bacterium. Infect. Immun. 72 (2004) 5750-5758
83. Weizman Z., Asli G., and Alsheikh A. Effect of a probiotic infant formula on infections in child care centers: comparison of two probiotic agents. Pediatrics 115 (2005) 5-9
84. Wen K., Azevedo M.S., Gonzalez A., Zhang W., Saif L.J., Li G., Yousef A., and Yuan L. Toll-like receptor and innate cytokine responses induced by lactobacilli colonization and human rotavirus infection in gnotobiotic pigs. Vet. Immunol. Immunopathol. 127 (2009) 304-315
85. Yamano T., Iino H., Takada M., Blum S., Rochat F., and Fukushima Y. Improvement of the human intestinal flora by ingestion of the probiotic strain Lactobacillus johnsonii La1. Br. J. Nutr. 95 (2006) 303-312
86. Yan F., and Polk D.B. Probiotic bacterium prevents cytokine-induced apoptosis in intestinal epithelial cells. J. Biol. Chem. 277 (2002) 50959-50965
87. Yan F., Cao H., Cover T.L., Whitehead R., Washington M.K., and Polk D.B. Soluble proteins produced by probiotic bacteria regulate intestinal epithelial cell survival and growth. Gastroenterology 132 (2007) 562-575
88. Yang F., Wang J., Li X., Ying T., Qiao S., Li D., and Wu G. 2-DE and MS analysis of interactions between Lactobacillus fermentum I5007 and intestinal epithelial cells. Electrophoresis 28 (2007) 4330-4339
89. Zocco M.A., dal Verme L.Z., Cremonini F., Piscaglia A.C., Nista E.C., Candelli M., Novi M., Rigante D., Cazzato I.A., Ojetti V., Armuzzi A., Gasbarrini G., and Gasbarrini A. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment. Pharmacol. Ther. 23 (2006) 1567-1574
90. Zyrek A.A., Cichon C., Helms S., Enders C., Sonnenborn U., and Schmidt M.A. Molecular mechanisms underlying the probiotic effects of Escherichia coli Nissle 1917 involve ZO-2 and PKCzeta redistribution resulting in tight junction and epithelial barrier repair. Cell. Microbiol. 9 (2007) 804-816